Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tetracyclic compound capable of promoting in-vitro proliferation of double-negative T cells

A tetracyclic compound, cell body technology, applied in organic chemistry, drug combination, anti-tumor drugs, etc., can solve the problem of difficult to achieve cell volume, and achieve the promotion of cell cycle and mitosis, efficient promotion of DNT cell proliferation, and promotion of construction. Effect

Active Publication Date: 2015-12-30
艾美斐生物医药科技(上海)有限公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, given that DNT cells only account for about 1-5% of peripheral blood mononuclear cells (PBMC), it is difficult to achieve the amount of cells required for CAR-DN-T therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tetracyclic compound capable of promoting in-vitro proliferation of double-negative T cells
  • Tetracyclic compound capable of promoting in-vitro proliferation of double-negative T cells
  • Tetracyclic compound capable of promoting in-vitro proliferation of double-negative T cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0028] IMC-00239 can promote the expansion of CAR-DN-T without affecting the cell killing function of CAR-DN-T.

[0029] After the DNT cells sorted from the peripheral blood mononuclear cells of healthy donors were infected with chimeric antigen receptor lentivirus, they were treated with T cell receptor antibody and cytokine (Vehicle) and 0.5μMIC-00239 combined with T cells. Somatic antibody and cytokine stimulation, cultured for 14 days. The number of cells in the IMC-00239 group is about 7 times higher than that in the Vehicle group. Figure 6 shown. Comparing the IMC-00239 group with the cytokine group CAR-DN-T for cell killing ability, it was found that IMC-00239 had no significant effect on the cell killing ability of CAR-DN-T, refer to Figure 7 shown.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a tetracyclic compound capable of promoting in-vitro proliferation of double-negative T cells. The tetracyclic compound is IMC-00239, and the molecular formula of the tetracyclic compound is shown in the description. The invention relates to the tetracyclic compound which can be used for promoting in-vitro proliferation of the CD3<+> / CD4<-> / CD8<->double-negative T (DN T) cells and is selected from a compound library according to a high-throughput screening method, and provides a pharmaceutically acceptable salt and a prodrug of the tetracyclic compound. The compound is a restrainer of a Wnt signal channel, and can induce degradation of beta-Catenin of the DN T cells, shorten cell cycle and promote karyokinesis when being used in in-vitro experiments. The compound can effectively promote the construction of a CAR-DN-T in-vitro proliferation system, and help implementation of a CAR-DN-T cell factory.

Description

technical field [0001] The invention relates to a tetracyclic compound that promotes double-negative T cell proliferation in vitro in the field of biomedicine, in particular to a compound that promotes CD3 + / CD4 - / CD8 - Tetracyclic compounds for in vitro proliferation of double-negative T (DNT) cells. Background technique [0002] Immunotherapy is considered to be the third revolution in cancer treatment, in which chimeric antigen receptor T cell (CAR-T) technology targets CD19 + The excellent clinical trial results of acute B-lymphoblastic leukemia have attracted widespread attention in the medical field, and it is considered to be the most promising therapy to cure tumors. [0003] However, the current CAR-T therapy is to use the patient's own T cells to transform CAR-T cells, which has high requirements on the number, vitality and proliferation ability of the patient's T cells. It has been found in clinical trial practice that more than 80% of patients' T cells do n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D209/52A61P35/00
CPCC07D209/52
Inventor 范国煌廖诗骅陈曦李润生
Owner 艾美斐生物医药科技(上海)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com